Presented by Dr Fred Beasley this webinar will explain how to select the most appropriate models for your preclinical obesity studies, including reviewing polygenic vs monogenic models and recommendations based on drug modes of action. We'll also review best practice in obesity study design to maximize data outcomes.

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

Presented by Dr. Leigh Goedeke of Yale School of Medicine, this webinar details using spontaneous NHP models of NAFLD and metabolic syndrome to assess a controlled-release mitochondrial protonophore (CRMP). Explore proof-of-concept data from these clinically relevant models, supporting the development of novel liver-targeted mitochondrial uncouplers to treat human NASH and T2D.

Learn more about novel preclinical techniques for optimizing diabetes studies with spontaneously diabetic NHPs. Explore continuous glucose monitoring and banana tolerance test case studies, and learn how reducing invasiveness and stress leads to improved animal welfare, study data, and clinical outcomes.

The tumor homograft MuScreen^TM is now available in a smaller panel, covering 6 different indications and with each model harboring clinically-relevant mutations. Screen your I/O agent efficacy in these fully immunocompetent models that have never been passaged in vitro.

Explore the benefits of imaging orthotopic, metastatic models. Read our new White Paper to learn more about key model utilities for studying disease progression and metastasis, and for assessing novel agents for different disease stages.

Presented by Dr Thomas Scullion this webinar focuses on using NHPs for the preclinical assessment of immunotherapy toxicity. Explore how clinical trials are de-risked by evaluating immuno-safety early in drug discovery, and how to incorporate exploratory toxicology NHP studies into your preclinical programs.

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

We presented posters on our unique translational NASH model at the ADA Scientific Sessions this year. Download our latest data on NASH induction in the dysmetabolic MS-NASH mouse (formerly FATZO), and accelerated disease induction resulting in a model featuring both severe fibrosis and dysmetabolism.

Learn how to optimize syngeneic translatability through proof of concept and target engagement studies. Read our new White Paper to explore how panels of syngeneic models are used to evaluate new single agent and combination regimens, uncover biomarkers of I/O response, and discover common PD markers for predicting population response.

Advance your NASH therapeutics with the inherently dysmetabolic, obese, and diabetic MS-NASH mouse (formerly FATZO). Learn more about standard NASH induction on Western diet plus fructose, as well as accelerated disease progression and exacerbated pathology with CCl₄ administration. Explore new CCl₄ data, including improved lipid profile and NAS score with OCA treatment.